PRG-1801 clinical trials
Also written PRG-1801.
How each study uses PRG-1801 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the PRG-1801 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PRG-1801
- 2
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Tongji Hospital (1) · Lingli Dong (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test PRG-1801.
- Dec 2026Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)Early Phase 1 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Jul 2027Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related DiseaseEarly Phase 1 · Tongji Hospital
Studies
Open first, then newest update. How each study uses PRG-1801 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)RecruitingEarly Phase 1Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT06519565Written as PRG-1801How we know
- Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related DiseaseRecruitingEarly Phase 1Tongji HospitalNCT06497387Written as PRG-1801How we know
- Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T CellsRecruitingNot applicableLingli DongNCT06277427Written as PRG-1801 (CAR-T against BCMA)How we know